Share on LinkedInShare on LinkedIn

ARTICLE · 22 APRIL 2024

MDL Panel Grants Transfer Of Aflibercept BPCIA Case

As we previously reported, on January 11, 2024, Regeneron Pharmaceuticals, Inc. ("Regeneron") moved to establish a multi-district litigation ("MDL") for its aflibercept BPCIA litigation...

United StatesIntellectual Property

As we previously reported, on January 11, 2024, Regeneron Pharmaceuticals, Inc. ("Regeneron") moved to establish a multi-district litigation ("MDL") for its aflibercept BPCIA litigation, and to transfer its case against Amgen, Inc. ("Amgen") to the Northern District of West Virginia under 28 U.S.C. § 1407. The litigation consists of six actions—one against Amgen, pending in the Central District of California, and five pending in the Northern District of West Virginia (assigned to Chief Judge Thomas S. Kleeh) against Mylan/Biocon, Celltrion, Formycon, and two against Samsung Bioepis.

On February 2, 2024, Samsung Bioepis, Celltrion, and Formycon filed a joint opposition to Regeneron's motion. Amgen filed a separate opposition brief the same day.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from